Press Release

Biocon Limited announced that its partner, Duopharma Biotech, secured multiple insulin tenders from Malaysia's Ministry of Health, valued at over MYR 225 million. Biocon's Malaysian subsidiary will supply short-acting recombinant human insulin, insulin glargine, and insulin aspart under these contracts, which include a three-year human insulin agreement and two-year agreements for insulin glargine and aspart. This reinforces Biocon's commitment to diabetes care in Malaysia, ensuring continued access to high-quality, cost-effective insulin therapies and strengthening its market presence.